Entegris (ENTG) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
10 Feb, 2026Executive summary
Q4 2025 net sales were $823.9M, down 3% year-over-year but up 2% sequentially, with non-GAAP EPS at $0.70 and GAAP EPS at $0.32, both near or above guidance high-end.
Adjusted EBITDA for Q4 2025 was $228.1M (27.7% margin), down 8.2% year-over-year but up 3.4% sequentially.
2025 growth was driven by strong demand in liquid filtration, selective etch, and CMP consumables, especially in advanced technologies.
Strategic priorities include deepening customer relationships, ramping new facilities, improving free cash flow, and increasing local-for-local manufacturing, especially for China.
Free cash flow improved in 2025, with expectations for further cash generation and de-leveraging in 2026.
Financial highlights
Q4 2025 gross margin was 43.8% GAAP and 44% non-GAAP; adjusted operating margin was 21.2%.
Q4 2025 net income was $49.4M; full-year net sales were $3,196.6M with net income of $235.6M.
Free cash flow for Q4 2025 was $134M, with a full-year margin of 12.7%.
CapEx for 2025 was $299M (9% of sales); year-end cash was $360.4M.
Long-term debt at year-end was $3,697.6M; net leverage at 3.8x.
Outlook and guidance
Q1 2026 sales expected between $785M–$825M; non-GAAP EPS $0.70–$0.78; adjusted EBITDA margin 26.5%–27.5%.
Q1 2026 GAAP net income guidance: $65M–$77M; diluted EPS: $0.43–$0.51.
Full-year 2026 CapEx expected at $250M; net leverage targeted below 3.5x by year-end.
Industry MSI growth expected mid-single digits; company expects to outperform market if node transitions materialize.
Q2 2026 sales expected to increase 1%–3% sequentially.
Latest events from Entegris
- Annual meeting to vote on directors, compensation, auditor, and key shareholder rights changes.ENTG
Proxy filing23 Mar 2026 - Proxy covers leadership transition, governance reforms, and performance-based compensation changes.ENTG
Proxy filing23 Mar 2026 - Strategic growth, governance reforms, and enhanced ESG drive long-term value creation.ENTG
Proxy Filing6 Mar 2026 - Q2 sales rose sequentially with strong margins; Q3 guidance and investments support further growth.ENTG
Q2 20242 Feb 2026 - Adjusted sales up 7% year-over-year; Q4 outlook signals margin strength and cost savings.ENTG
Q3 202417 Jan 2026 - Q4 2024 delivered double-digit adjusted sales growth and margin expansion, beating guidance.ENTG
Q4 20248 Jan 2026 - Q2 2025 sales were $792.4M, with Q3 non-GAAP EPS guided at $0.68–$0.75.ENTG
Q2 202517 Dec 2025 - Strong 2024 growth, robust governance, and key votes on directors, pay, auditor, and voting rights.ENTG
Proxy Filing1 Dec 2025 - Q1 2025 net sales rose 5% adjusted, with margin gains and tariff risks impacting outlook.ENTG
Q1 202517 Nov 2025